Compare KINS & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KINS | NBP |
|---|---|---|
| Founded | 1886 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.7M | 212.8M |
| IPO Year | 2013 | N/A |
| Metric | KINS | NBP |
|---|---|---|
| Price | $16.23 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 94.7K | ★ 646.2K |
| Earning Date | 05-07-2026 | 04-07-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 94.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $214,867,301.00 | N/A |
| Revenue This Year | $24.23 | N/A |
| Revenue Next Year | $18.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.50 | N/A |
| 52 Week Low | $13.08 | $1.46 |
| 52 Week High | $19.42 | $5.19 |
| Indicator | KINS | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 58.59 | 26.54 |
| Support Level | $14.17 | N/A |
| Resistance Level | $16.73 | $1.95 |
| Average True Range (ATR) | 0.52 | 0.12 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 79.66 | 6.19 |
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.